These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17385940)

  • 1. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
    Jost WH; Blümel J; Grafe S
    Drugs; 2007; 67(5):669-83. PubMed ID: 17385940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.
    Santamato A; Micello MF; Panza F; Fortunato F; Pilotto A; Giustini A; Testa A; Fiore P; Ranieri M; Spidalieri R
    Eur J Phys Rehabil Med; 2013 Aug; 49(4):483-9. PubMed ID: 23480980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.
    Park J; Lee MS; Harrison AR
    Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the use of botulinum neurotoxins in facial esthetics.
    Flynn TC
    J Cosmet Dermatol; 2012 Mar; 11(1):42-50. PubMed ID: 22360334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL
    Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review.
    Sattler G
    J Drugs Dermatol; 2010 Sep; 9(9):1065-71. PubMed ID: 20865836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine use of Xeomin in patients previously treated with Botox: long term results.
    Dressler D
    Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IncobotulinumtoxinA in esthetics.
    Kerscher M; Yutskovskaya Y; Flynn TC
    J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.